Free Trial

Talphera (TLPH) Competitors

Talphera logo
$0.52 +0.01 (+1.76%)
Closing price 07/11/2025 03:57 PM Eastern
Extended Trading
$0.52 -0.01 (-0.96%)
As of 07/11/2025 04:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TLPH vs. EGRX, MRSN, KPTI, STTK, LTRN, ELYM, PEPG, ITRM, AKTX, and ATHE

Should you be buying Talphera stock or one of its competitors? The main competitors of Talphera include Eagle Pharmaceuticals (EGRX), Mersana Therapeutics (MRSN), Karyopharm Therapeutics (KPTI), Shattuck Labs (STTK), Lantern Pharma (LTRN), Eliem Therapeutics (ELYM), PepGen (PEPG), Iterum Therapeutics (ITRM), Akari Therapeutics (AKTX), and Alterity Therapeutics (ATHE). These companies are all part of the "pharmaceutical products" industry.

Talphera vs. Its Competitors

Eagle Pharmaceuticals (NASDAQ:EGRX) and Talphera (NASDAQ:TLPH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

In the previous week, Eagle Pharmaceuticals and Eagle Pharmaceuticals both had 1 articles in the media. Talphera's average media sentiment score of 1.89 beat Eagle Pharmaceuticals' score of 0.00 indicating that Talphera is being referred to more favorably in the news media.

Company Overall Sentiment
Eagle Pharmaceuticals Neutral
Talphera Very Positive

Eagle Pharmaceuticals has higher revenue and earnings than Talphera.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eagle Pharmaceuticals$257.55M0.18$35.64MN/AN/A
Talphera$650K16.40-$13M-$0.45-1.16

Eagle Pharmaceuticals has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Talphera has a beta of -0.11, indicating that its stock price is 111% less volatile than the S&P 500.

Talphera has a consensus target price of $5.00, indicating a potential upside of 861.54%. Given Talphera's stronger consensus rating and higher probable upside, analysts clearly believe Talphera is more favorable than Eagle Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eagle Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Talphera
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
3.50

Eagle Pharmaceuticals' return on equity of 0.00% beat Talphera's return on equity.

Company Net Margins Return on Equity Return on Assets
Eagle PharmaceuticalsN/A N/A N/A
Talphera N/A -130.28%-59.25%

85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. Comparatively, 37.7% of Talphera shares are owned by institutional investors. 28.9% of Eagle Pharmaceuticals shares are owned by insiders. Comparatively, 3.2% of Talphera shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Eagle Pharmaceuticals beats Talphera on 7 of the 13 factors compared between the two stocks.

Get Talphera News Delivered to You Automatically

Sign up to receive the latest news and ratings for TLPH and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TLPH vs. The Competition

MetricTalpheraMED IndustryMedical SectorNASDAQ Exchange
Market Cap$10.48M$2.45B$5.61B$9.11B
Dividend YieldN/A1.79%5.24%4.01%
P/E Ratio-1.169.4227.9620.25
Price / Sales16.40729.02430.8999.65
Price / CashN/A165.3637.4658.16
Price / Book1.114.608.045.49
Net Income-$13M$31.26M$3.18B$250.27M
7 Day Performance11.83%4.80%3.67%4.80%
1 Month Performance2.26%5.42%4.09%7.68%
1 Year Performance-44.09%-4.36%29.58%16.36%

Talphera Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TLPH
Talphera
1.9992 of 5 stars
$0.52
+1.8%
$5.00
+861.5%
-42.3%$10.48M$650K-1.1619Positive News
EGRX
Eagle Pharmaceuticals
2.4587 of 5 stars
$3.00
flat
N/A-41.1%$38.96M$257.55M0.00100News Coverage
Gap Down
MRSN
Mersana Therapeutics
4.029 of 5 stars
$0.31
+1.9%
$5.20
+1,577.4%
-83.1%$38.64M$40.50M-0.53150Gap Up
KPTI
Karyopharm Therapeutics
3.9295 of 5 stars
$4.47
+5.7%
$43.20
+866.4%
-68.5%$38.62M$145.24M-0.34380News Coverage
Analyst Forecast
Gap Down
STTK
Shattuck Labs
3.7029 of 5 stars
$0.80
+3.5%
$7.50
+838.3%
-79.9%$38.29M$5.72M-0.58100Positive News
LTRN
Lantern Pharma
3.1387 of 5 stars
$3.55
+12.7%
$25.00
+604.2%
-12.4%$38.27MN/A-1.9320Positive News
Gap Up
High Trading Volume
ELYM
Eliem Therapeutics
N/A$1.28
+1.6%
N/A-80.9%$38.08MN/A-2.429
PEPG
PepGen
3.1025 of 5 stars
$1.16
+4.5%
$7.67
+560.9%
-92.7%$37.96MN/A-0.3730
ITRM
Iterum Therapeutics
1.7313 of 5 stars
$0.93
+0.7%
$9.00
+867.6%
-29.6%$37.20MN/A-0.9410
AKTX
Akari Therapeutics
0.8644 of 5 stars
$1.13
+1.8%
N/A-68.0%$36.36MN/A0.009
ATHE
Alterity Therapeutics
2.1768 of 5 stars
$4.09
+5.7%
$12.00
+193.4%
+125.0%$36.28MN/A0.0010Gap Up

Related Companies and Tools


This page (NASDAQ:TLPH) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners